Na NS Healthcare Staff Writer 16 Mei 2022
E hāʻawi ʻia ʻo Mounjaro i ʻeono mau kaila, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, a me 15mg, me ka peni injector auto-injector a Lilly e hele mai me kahi nila huna huna.
ʻO Mounjaro kahi agonist receptor GIP a me GLP-1.(Ke kālā: Lilly USA, LLC.)
Ua loaʻa iā Eli Lilly a me Company (Lilly) ka ʻae ʻana o ka US Food and Drug Administration (FDA) no kāna injection Mounjaro (tirzepatide) e mālama i ka maʻi diabetes type 2 i nā pākeke.
ʻO Mounjaro kahi mole hoʻokahi e hoʻāla i nā hormones incretin kūlohelohe glucose-dependent insulinotropic polypeptide (GIP) a me ka glucagon-like peptide-1 (GLP-1) receptor agonist.
Hōʻike ʻia ka lāʻau lapaʻau e like me ka mālama ʻana i hoʻokahi pule, hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi i ka mana glycemic i nā pākeke me ka maʻi diabetes type 2.
E hāʻawi ʻo Lilly iā Mounjaro, ka mea mua a me ka FDA i ʻae ʻia GIP a me GLP-1 receptor agonist, i ʻeono mau kau, me 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, a me 15mg.
Ke hoʻolālā nei ka hui e hoʻolaha i ka lāʻau lapaʻau ma US, me kāna peni injector auto-i hele mai me kahi nila huna i hoʻopili mua ʻia, i loko o kekahi mau pule.
Ua ʻōlelo ʻo Pelekikena Lilly Diabetes Mike Mason: "He hoʻoilina ko Lilly kokoke i 100 mau makahiki o ka mālama holomua ʻana i ka poʻe e noho ana me ka maʻi maʻi diabetes - ʻaʻole e hoʻoholo i nā hopena o kēia manawa.
"ʻAʻole mākou hauʻoli i ka ʻike ʻana ʻo ka hapalua o ka ʻoi aku ma mua o 30 miliona ʻAmelika e noho nei me ka maʻi maʻi type 2 ʻaʻole i hiki i kā lākou pae glucose koko.
"ʻOliʻoli mākou i ka hoʻolauna ʻana iā Mounjaro, ka mea i hōʻike i ka papa mua o ka lāʻau maʻi diabetes type 2 i hoʻokomo ʻia i loko o kahi ʻumi makahiki a hoʻokomo i kā mākou misionari e lawe mai i nā lāʻau lapaʻau hou i ke kaiāulu diabetes."
Ua hoʻokumu ʻia ka ʻae ʻana o FDA iā Mounjaro ma nā hopena mai ka papahana ʻo Phase 3 SURPASS i hoʻomaka i ka hopena o 2018, ʻelima mau hoʻokolohua honua a me ʻelua mau hoʻokolohua kūloko ma Iapana.
Ua loiloi ka papahana i ka pono a me ka palekana o Mounjaro 5mg, 10mg a me 15mg ma ke ʻano he monotherapy, a ma ke ʻano he mea hoʻohui i nā lāʻau lapaʻau maʻamau no ka maʻi diabetes type 2.
Ma ka papahana SURPASS, ʻo Mounjaro 5mg ka hopena i ka hōʻemi ʻana o A1C e 1.8% i ka 2.1%, a ʻo Mounjaro 10mg a me Mounjaro 15mg i hāʻawi i ka 1.7% a me ka 2.4% A1C hōʻemi.
ʻAʻole i hōʻike ʻia ka lāʻau lapaʻau no ka pohō kaumaha;akā naʻe, ua lilo nā poʻe i mālama ʻia me Mounjaro i ka 12lb (5mg) i ka 25lb (15mg) kaumaha ma ka awelika, wahi a ka firm.
ʻO ke ʻano o ka hoʻololi ʻana i ke kaumaha o ke kino kekahi o nā koʻikoʻi koʻikoʻi ma nā haʻawina SURPASS āpau.
ʻO nā maʻi i mālama ʻia me Mounjaro i hōʻike i nā hopena ʻaoʻao e pili ana i ka nausea, ka maʻi maʻi, ka emi ʻana o ka makemake, ka luaʻi ʻana, constipation, dyspepsia, a me ka ʻeha ʻōpū.
Eia kekahi, hele mai ʻo Mounjaro me kahi ʻōlelo aʻoaʻo e pili ana i nā ʻōpū C-cell thyroid.Hoʻopaʻa ʻia ka lāʻau lapaʻau i nā mea maʻi me kahi moʻolelo pilikino a ʻohana paha o ka medullary thyroid carcinoma a i ʻole i nā mea maʻi me Multiple Endocrine Neoplasia Syndrome type 2.
ʻAʻole i loiloi ʻia ʻo Mounjaro i nā mea maʻi me ka mōʻaukala o ka pancreatitis a ʻaʻole i kuhikuhi ʻia no ka hoʻohana ʻana i nā mea maʻi me ka maʻi diabetes type 1, i ʻōlelo ʻia.Lilly.
Ka manawa hoʻouna: Mei-24-2022